BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies by Mariam Markouli, Maria N. Pagoni, Panagiotis Diamantopoulos

“…Unfortunately, although BCL-2 inhibition has shown remarkable results in a range of B-cell lymphoid cancers as well as acute myeloid leukemia (AML), the development of resistance significantly reduces response rates in specific tumor subtypes. …”
Get full text

Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy by Wei Hua, Jie Liu, Yue Li, Hua Yin, Hao‐Rui Shen, Jia‐Zhu Wu, Yi‐Lin Kong, Bi‐Hui Pan, Jun‐Heng Liang, Li Wang, Jian‐Yong Li, Rui Gao, Jin‐Hua Liang, Wei Xu

“…Programmed cell death (PCD) pathways are crucial in the advancement of lymphoma and serve as significant prognostic markers for individuals afflicted with lymphoid cancers. To identify robust prognostic biomarkers that can guide personalized management for less‐defined subtype DLBCL patients, we integrated multi‐omics data derived from 339 standard R‐CHOP‐treated patients diagnosed with less‐defined subtype DLBCL from three independent cohorts. …”
Get full text